Alkermes (ALKS) Deferred Taxes (2011 - 2026)
Alkermes' (ALKS) quarterly Deferred Taxes came in at $9.1 million in Q2 2026, up 367.21% year-over-year from $1.9 million in Q2 2025, and up 203.61% quarter-over-quarter from -$8.8 million in Q1 2026.
Analysis
Alkermes (ALKS) Deferred Taxes (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Deferred Taxes for 16 consecutive years, with $9.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Deferred Taxes rose 367.21% year-over-year to $9.1 million in Q2 2026; TTM through Jun 2026 was $28.3 million, a 58.14% increase from a year earlier, with the FY2024 full-year figure at $40.5 million, up 140.56% from the prior year.
- Deferred Taxes was $9.1 million for Q2 2026 at Alkermes, up from -$8.8 million in the prior quarter.
- Over five years, Deferred Taxes peaked at $31.4 million in Q3 2025 and troughed at -$52.5 million in Q4 2023.
- A 5-year average of -$3.6 million and a median of -$2.0 million in 2023 frame the typical range for Deferred Taxes.
- Across the five-year window, Deferred Taxes plunged 657.58% in 2022 and soared 803.42% in 2024, its largest moves.
- Over 5 years, Deferred Taxes stood at $21.3 million in 2022, then sank by 346.81% to -$52.5 million in 2023, then surged by 115.63% to $8.2 million in 2024, then soared by 282.43% to $31.4 million in 2025, then tumbled by 71.0% to $9.1 million in 2026.
- The last three Deferred Taxes figures came in at $9.1 million (Q2 2026), -$8.8 million (Q1 2026), and $31.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -479.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -195.00 Mn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -544.00 Mn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -1.32 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 115.62 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 25.70 Mn |
| 10 | Alkermes | 7.58 Bn | 6.92 Bn | 397.90 Mn | 9.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.10 Mn |
| Mar 31, 2026 | -8.79 Mn |
| Sep 30, 2025 | 31.39 Mn |
| Jun 30, 2025 | -3.41 Mn |
| Mar 31, 2025 | 2.51 Mn |
| Dec 31, 2024 | 8.21 Mn |
| Sep 30, 2024 | 10.59 Mn |
| Jun 30, 2024 | 14.21 Mn |
| Mar 31, 2024 | 7.52 Mn |
| Dec 31, 2023 | -52.52 Mn |
| Sep 30, 2023 | -9.25 Mn |
| Jun 30, 2023 | -2.02 Mn |
| Mar 31, 2023 | -36.12 Mn |
| Dec 31, 2022 | 21.28 Mn |
| Sep 30, 2022 | -13.26 Mn |
| Jun 30, 2022 | -11.51 Mn |
| Mar 31, 2022 | -29.30 Mn |
| Dec 31, 2021 | 3.07 Mn |
| Sep 30, 2021 | -8.79 Mn |
| Jun 30, 2021 | 5.55 Mn |